The FDA has approved Elxonris (tagraxofusperzs) infusion to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in patients two years and older. This is the first FDA approved therapy specifically for BPDCN. Elzonris is a targeted investigational therapy directed to CD123, a cell surface receptor expressed on a range of malignancies. In the first cohort trial, 54% of the patients achieved complete remission (CR) or CR with a skin abnormality not indicative of active disease. This breakthrough therapy provides an alternative for patients with BPDCN who can’t tolerate intensive chemotherapy followed by bone marrow transplantation.
Read the full FDA press release here